Nicole M Enman1, Kayti Arthur2, Sara J Ward2, Shane A Perrine3, Ellen M Unterwald4. 1. Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania; Center for Substance Abuse Research (NME, EMU), Temple University School of Medicine, Philadelphia, Pennsylvania. Electronic address: nicole.enman@temple.edu. 2. Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania. 3. Department of Psychiatry and Behavioral Neurosciences (SAP), Wayne State University School of Medicine, Detroit, Michigan. 4. Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania; Center for Substance Abuse Research (NME, EMU), Temple University School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Posttraumatic stress disorder (PTSD) co-occurs with substance use disorders at high rates, but the neurobiological basis of this relationship is largely unknown. PTSD and drug addiction each involve dysregulation of brain reward circuitry; therefore, the identification of pathology of the mesolimbic dopamine system may aid in understanding their functional relationship. Dopamine reward dysfunction also may be relevant to the mechanisms underlying the PTSD symptoms of anhedonia and emotional numbing. METHODS: Single-prolonged stress (SPS) was used as a rat model of PTSD, and a series of behavioral and neuropharmacologic assays were applied to assess the impact of SPS on reward, cocaine intake, and components of the striatal dopamine system. RESULTS: Exposure to SPS increased anhedonia-like behaviors and decreased the rewarding properties of cocaine compared with control handling. Altered cocaine intake during extended access self-administration sessions was observed in rats exposed to SPS, further suggesting a difference in the reinforcing properties of cocaine following severe stress. SPS reduced tissue content of dopamine and its metabolites in the striatum, as well as altered striatal dopamine transporter and D2, but not D1, receptor densities. CONCLUSIONS: These results support a role for altered dopaminergic transmission in reduced reward function in PTSD. Pathology of the dopamine system and the degradation of reward processes may contribute to PTSD symptomology and have implications for co-occurring psychiatric disorders such as substance abuse or depression.
BACKGROUND:Posttraumatic stress disorder (PTSD) co-occurs with substance use disorders at high rates, but the neurobiological basis of this relationship is largely unknown. PTSD and drug addiction each involve dysregulation of brain reward circuitry; therefore, the identification of pathology of the mesolimbic dopamine system may aid in understanding their functional relationship. Dopamine reward dysfunction also may be relevant to the mechanisms underlying the PTSD symptoms of anhedonia and emotional numbing. METHODS: Single-prolonged stress (SPS) was used as a rat model of PTSD, and a series of behavioral and neuropharmacologic assays were applied to assess the impact of SPS on reward, cocaine intake, and components of the striatal dopamine system. RESULTS: Exposure to SPS increased anhedonia-like behaviors and decreased the rewarding properties of cocaine compared with control handling. Altered cocaine intake during extended access self-administration sessions was observed in rats exposed to SPS, further suggesting a difference in the reinforcing properties of cocaine following severe stress. SPS reduced tissue content of dopamine and its metabolites in the striatum, as well as altered striatal dopamine transporter and D2, but not D1, receptor densities. CONCLUSIONS: These results support a role for altered dopaminergic transmission in reduced reward function in PTSD. Pathology of the dopamine system and the degradation of reward processes may contribute to PTSD symptomology and have implications for co-occurring psychiatric disorders such as substance abuse or depression.
Authors: Drake Morgan; Kathleen A Grant; H Donald Gage; Robert H Mach; Jay R Kaplan; Osric Prioleau; Susan H Nader; Nancy Buchheimer; Richard L Ehrenkaufer; Michael A Nader Journal: Nat Neurosci Date: 2002-02 Impact factor: 24.884
Authors: Laura Nawijn; Mirjam van Zuiden; Jessie L Frijling; Saskia B J Koch; Dick J Veltman; Miranda Olff Journal: Neurosci Biobehav Rev Date: 2015-01-29 Impact factor: 8.989
Authors: Andrew L Eagle; Robby Singh; Robert J Kohler; Amy L Friedman; Chelsea P Liebowitz; Matthew P Galloway; Nicole M Enman; Emily M Jutkiewicz; Shane A Perrine Journal: Behav Brain Res Date: 2015-02-21 Impact factor: 3.332
Authors: Zachary D Brodnik; Emily M Black; Meagan J Clark; Kristen N Kornsey; Nathaniel W Snyder; Rodrigo A España Journal: Neuropharmacology Date: 2017-08-01 Impact factor: 5.250
Authors: Elizabeth A Olson; Roselinde H Kaiser; Diego A Pizzagalli; Scott L Rauch; Isabelle M Rosso Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-11-16
Authors: Christopher J Fitzpatrick; Lakshmikripa Jagannathan; Elijah D Lowenstein; Terry E Robinson; Jill B Becker; Jonathan D Morrow Journal: Behav Brain Res Date: 2018-08-02 Impact factor: 3.332
Authors: Andrea Pelletier-Baldelli; Gregory P Strauss; Franchesca S Kuhney; Charlotte Chun; Tina Gupta; Lauren M Ellman; Jason Schiffman; Vijay A Mittal Journal: J Psychiatr Res Date: 2021-01-11 Impact factor: 4.791